Principal Financial Group
ESPR

Principal Financial Group’s Esperion Therapeutics ESPR Stock Holding History

Principal Financial Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
456,478
+33,702
+8% +$94.3K ﹤0.01% 1890
2026
Q1 		$1.16M Buy
422,776
+146,484
+53% +$464K ﹤0.01% 1911
2025
Q4 		$1.02M Buy
276,292
+86,236
+45% +$279K ﹤0.01% 1951
2025
Q3 		$504K Sell
190,056
-203,234
-52% -$393K ﹤0.01% 2045
2025
Q2 		$387K Buy
393,290
+380,034
+2,867% +$381K ﹤0.01% 2030
2025
Q1 		$19.1K Buy
13,256
+1,157
+10% +$2.13K ﹤0.01% 2151
2024
Q4 		$26.6K Sell
12,099
-3,245
-21% -$7.57K ﹤0.01% 2190
2024
Q3 		$25.3K Sell
15,344
-5,086
-25% -$10.3K ﹤0.01% 2205
2024
Q2 		$45.4K Sell
20,430
-8,721
-30% -$20.5K ﹤0.01% 2291
2024
Q1 		$78.1K Sell
29,151
-4,482
-13% -$10.9K ﹤0.01% 2300
2023
Q4 		$101K Sell
33,633
-803
-2% -$1.04K ﹤0.01% 2273
2023
Q3 		$33.7K Buy
34,436
+2,898
+9% +$4.19K ﹤0.01% 2376
2023
Q2 		$43.8K Buy
31,538
+12,248
+63% +$17.1K ﹤0.01% 2369
2023
Q1 		$30.7K Sell
19,290
-1,448
-7% -$7.47K ﹤0.01% 2404
2022
Q4 		$129K Buy
20,738
+3,882
+23% +$27.8K ﹤0.01% 2260
2022
Q3 		$113K Sell
16,856
-142
-0.8% -$975 ﹤0.01% 2312
2022
Q2 		$108K Buy
16,998
+6,511
+62% +$36.9K ﹤0.01% 2383
2022
Q1 		$49K Buy
+10,487
New +$45K ﹤0.01% 2487
2020
Q4 		– Sell
-5,559
Closed -$207K – 2428
2020
Q3 		$207K Sell
5,559
-4,551
-45% -$180K ﹤0.01% 2202
2020
Q2 		$518K Buy
+10,110
New +$423K ﹤0.01% 1960
2020
Q1 		– Sell
-3,966
Closed -$236K – 2214
2019
Q4 		$236K Buy
+3,966
New +$178K ﹤0.01% 2099
2018
Q2 		– Sell
-4,618
Closed -$334K – 2283
2018
Q1 		$334K Buy
4,618
+449
+11% +$33K ﹤0.01% 2004
2017
Q4 		$274K Buy
+4,169
New +$224K ﹤0.01% 2064

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Principal Financial Group's ESPR Position: Q2 2026 in Review

Principal Financial Group increased its Esperion Therapeutics (ESPR) stake by 8% in Q2 2026, buying an estimated $94.3K and bringing the position to 456,478 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

Principal Financial Group first reported a position in ESPR in Q4 2017 and has held it in 23 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Principal Financial Group held 456,478 shares of Esperion Therapeutics worth $1.44M as of Q2 2026.
  • Principal Financial Group bought 33,702 Esperion Therapeutics shares in Q2 2026, an estimated $94.3K.
  • Esperion Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1890 holding.
  • Principal Financial Group first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 23 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.